Published in Int J Cardiol on December 01, 2002
Peripartum cardiomyopathy: review of the literature. Yonsei Med J (2007) 0.98
Peripartum Cardiomyopathy: Current Therapeutic Perspectives. Curr Treat Options Cardiovasc Med (2004) 0.91
Peripartum cardiomyopathy: case reports. Perm J (2009) 0.86
Peripartum cardiomyopathy: current state of knowledge, new developments and future directions. Curr Cardiol Rev (2014) 0.85
The risk of cardiomyopathy in inherited epidermolysis bullosa. Br J Dermatol (2008) 0.83
Peripartum cardiomyopathy: A puzzle closer to solution. World J Cardiol (2014) 0.81
Serum selenium and ceruloplasmin in nigerians with peripartum cardiomyopathy. Int J Mol Sci (2015) 0.80
Peripartum cardiomyopathy: moving towards a more central role of genetics. Curr Cardiol Rev (2013) 0.79
Peripartum cardiomyopathy: an intriguing challenge. Case report with literature review. Curr Cardiol Rev (2009) 0.76
Peripartum cardiomyopathy: a current review. J Pregnancy (2010) 0.76
Peripartum cardiomyopathy. Ann Med Health Sci Res (2013) 0.75
Prevalence and predictors of right ventricular diastolic dysfunction in peripartum cardiomyopathy. J Echocardiogr (2017) 0.75
Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann Intern Med (2007) 3.67
Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev (2002) 3.15
Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol (2006) 2.18
Bacterial CpG induces hyper-IgM production in CD27(+) memory B cells in primary biliary cirrhosis. Gastroenterology (2005) 2.17
Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice. Hepatology (2009) 2.11
Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst (2003) 2.09
Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology (2008) 2.05
Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. J Exp Med (2002) 2.00
IL-2 receptor alpha(-/-) mice and the development of primary biliary cirrhosis. Hepatology (2006) 1.91
Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFβ receptor type II mice. Hepatology (2013) 1.78
Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology (2002) 1.72
Lack of immunological or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis. Gastroenterology (2004) 1.67
Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J Clin Invest (2002) 1.65
Depletion of CD4⁺ T cells abrogates post-peak decline of viremia in SIV-infected rhesus macaques. J Clin Invest (2011) 1.62
Availability of activated CD4+ T cells dictates the level of viremia in naturally SIV-infected sooty mangabeys. J Clin Invest (2008) 1.57
Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J Autoimmun (2008) 1.57
Regulatory T cells: development, function and role in autoimmunity. Autoimmun Rev (2005) 1.57
Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology (2009) 1.55
Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology (2010) 1.53
Heterogeneity of dendritic cells in the mouse liver: identification and characterization of four distinct populations. J Immunol (2003) 1.53
Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology (2006) 1.53
Chemical xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food additive, 2-octynoic acid. J Immunol (2005) 1.47
Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology (2003) 1.46
Adoptive transfer of CD8(+) T cells from transforming growth factor beta receptor type II (dominant negative form) induces autoimmune cholangitis in mice. Hepatology (2008) 1.45
Primary biliary cirrhosis is associated with altered hepatic microRNA expression. J Autoimmun (2009) 1.41
Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. J Autoimmun (2006) 1.41
Effects of selenium supplementation on cardiovascular disease incidence and mortality: secondary analyses in a randomized clinical trial. Am J Epidemiol (2006) 1.40
Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J (2005) 1.39
Selenium and anticarcinogenesis: underlying mechanisms. Curr Opin Clin Nutr Metab Care (2008) 1.37
Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis. Hepatology (2005) 1.37
Selenium as an anticancer nutrient: roles in cell proliferation and tumor cell invasion. J Nutr Biochem (2007) 1.34
Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite. Carcinogenesis (2008) 1.33
Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology (2013) 1.33
Natural killer T cells exacerbate liver injury in a transforming growth factor beta receptor II dominant-negative mouse model of primary biliary cirrhosis. Hepatology (2008) 1.30
Dengue virus-induced hemorrhage in a nonhuman primate model. Blood (2009) 1.29
Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail (2008) 1.29
The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun (2008) 1.25
A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis. Hepatology (2007) 1.23
Decreased NK cell frequency and function is associated with increased risk of KIR3DL allele polymorphism in simian immunodeficiency virus-infected rhesus macaques with high viral loads. J Immunol (2009) 1.22
Immunization with a xenobiotic 6-bromohexanoate bovine serum albumin conjugate induces antimitochondrial antibodies. J Immunol (2003) 1.21
Interleukin-15 but not interleukin-7 abrogates vaccine-induced decrease in virus level in simian immunodeficiency virus mac251-infected macaques. J Immunol (2007) 1.18
Increased killing activity and decreased cytokine production in NK cells in patients with primary biliary cirrhosis. J Autoimmun (2006) 1.17
B cells suppress the inflammatory response in a mouse model of primary biliary cirrhosis. Gastroenterology (2008) 1.17
Human tissue mast cells are an inducible reservoir of persistent HIV infection. Blood (2007) 1.17
Re-evaluation of PD-1 expression by T cells as a marker for immune exhaustion during SIV infection. PLoS One (2013) 1.16
IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy. Hepatology (2014) 1.15
Phylogenetic and immunological definition of four lipoylated proteins from Novosphingobium aromaticivorans, implications for primary biliary cirrhosis. J Autoimmun (2005) 1.14
Soluble PD-1 rescues the proliferative response of simian immunodeficiency virus-specific CD4 and CD8 T cells during chronic infection. Immunology (2008) 1.13
Induction of primary biliary cirrhosis in guinea pigs following chemical xenobiotic immunization. J Immunol (2007) 1.12
Differential mechanisms in the pathogenesis of autoimmune cholangitis versus inflammatory bowel disease in interleukin-2Ralpha(-/-) mice. Hepatology (2009) 1.11
New insights to the immunopathology and autoimmune responses in primary biliary cirrhosis. Cell Immunol (2006) 1.11
NOD mice and autoimmunity. Autoimmun Rev (2005) 1.09
Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF-β receptor type II mouse. J Autoimmun (2013) 1.08
Signaling through Toll-like receptors triggers HIV-1 replication in latently infected mast cells. J Immunol (2004) 1.07
Interaction between Toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis. Hepatology (2011) 1.07
Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. Clin Rev Allergy Immunol (2002) 1.07
Paucity of IL-21-producing CD4(+) T cells is associated with Th17 cell depletion in SIV infection of rhesus macaques. Blood (2012) 1.07
Transforming growth factor beta (TGF-beta) and autoimmunity. Autoimmun Rev (2005) 1.07
Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells. Hepatology (2014) 1.06
The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutr Cancer (2008) 1.06
Mechanistic aspects of the interaction between selenium and arsenic. J Inorg Biochem (2005) 1.05
Effects of high-protein diets on fat-free mass and muscle protein synthesis following weight loss: a randomized controlled trial. FASEB J (2013) 1.04
Expansion of bone marrow IFN-alpha-producing dendritic cells in New Zealand Black (NZB) mice: high level expression of TLR9 and secretion of IFN-alpha in NZB bone marrow. J Immunol (2004) 1.04
Prostate cancer risk and DNA damage: translational significance of selenium supplementation in a canine model. Carcinogenesis (2005) 1.04
Selenium and vitamin E supplementation for cancer prevention. JAMA (2009) 1.04
Peripartum cardiomyopathy in the Hospital Albert Schweitzer District of Haiti. Am J Obstet Gynecol (2002) 1.02
Defining the Optimal Selenium Dose for Prostate Cancer Risk Reduction: Insights from the U-Shaped Relationship between Selenium Status, DNA Damage, and Apoptosis. Dose Response (2009) 1.02
Infection of bone marrow cells by dengue virus in vivo. Exp Hematol (2011) 1.02
Deletion of interleukin-6 in mice with the dominant negative form of transforming growth factor beta receptor II improves colitis but exacerbates autoimmune cholangitis. Hepatology (2010) 1.01
Inverse association between glutathione peroxidase activity and both selenium-binding protein 1 levels and Gleason score in human prostate tissue. Prostate (2011) 1.00
Increased levels of chemokine receptor CXCR3 and chemokines IP-10 and MIG in patients with primary biliary cirrhosis and their first degree relatives. J Autoimmun (2005) 1.00
Studies on the potential use of CD38 expression as a marker for the efficacy of anti-retroviral therapy in HIV-1-infected patients in Thailand. Virology (2005) 1.00
Plasmacytoid dendritic cells of different origins have distinct characteristics and function: studies of lymphoid progenitors versus myeloid progenitors. J Immunol (2005) 0.99
B cell depletion therapy exacerbates murine primary biliary cirrhosis. Hepatology (2010) 0.99
The immunobiology of colitis and cholangitis in interleukin-23p19 and interleukin-17A deleted dominant negative form of transforming growth factor beta receptor type II mice. Hepatology (2012) 0.98
Clonality, activated antigen-specific CD8(+) T cells, and development of autoimmune cholangitis in dnTGFβRII mice. Hepatology (2013) 0.98
Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis. Hepatology (2014) 0.98
Optimization of in vitro expansion of macaque CD4 T cells using anti-CD3 and co-stimulation for autotransfusion therapy. J Med Primatol (2006) 0.97
Myeloperoxidase-positive inflammatory cells participate in bile duct damage in primary biliary cirrhosis through nitric oxide-mediated reactions. Hepatology (2003) 0.97
Antimitochondrial antibody heterogeneity and the xenobiotic etiology of primary biliary cirrhosis. Hepatology (2013) 0.96
Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate. J Natl Cancer Inst (2003) 0.96
Caspase induction by IgA antimitochondrial antibody: IgA-mediated biliary injury in primary biliary cirrhosis. Hepatology (2004) 0.95
Evidence for antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen processing and cross presentation in SIV-infected rhesus macaques. J Virol (2003) 0.94
CD4- plasmacytoid dendritic cells (pDCs) migrate in lymph nodes by CpG inoculation and represent a potent functional subset of pDCs. J Immunol (2005) 0.94
Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis. Hepatology (2011) 0.94
AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers. Hepatology (2007) 0.94
Mother-daughter peripartum cardiomyopathy. Int J Cardiol (2002) 0.94
Xenobiotic-induced loss of tolerance in rabbits to the mitochondrial autoantigen of primary biliary cirrhosis is reversible. J Immunol (2004) 0.92
Differential expression of intestinal trefoil factor in biliary epithelial cells of primary biliary cirrhosis. Hepatology (2002) 0.92
Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin. Clin Cancer Res (2008) 0.92
Is there a relation between Chlamydia infection and primary biliary cirrhosis? Clin Dev Immunol (2004) 0.92
Anti-CD3/28 mediated expansion of macaque CD4+ T cells is polyclonal and provides extended survival after adoptive transfer. J Med Primatol (2007) 0.92
Titers of antibody to common pathogens: relation to food-based interventions in rural Kenyan schoolchildren. Am J Clin Nutr (2003) 0.92
Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. Hepatology (2011) 0.92
Epidemiology and pathogenesis of primary biliary cirrhosis. J Clin Gastroenterol (2004) 0.92
Murine thymic plasmacytoid dendritic cells. Eur J Immunol (2003) 0.91
Selenium in bone health: roles in antioxidant protection and cell proliferation. Nutrients (2013) 0.91